NCT06610279View on ClinicalTrials.gov

A Study of TAK-951 in Healthy Adults

PHASE1TerminatedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

January 7, 2022

Primary Completion Date

September 21, 2023

Study Completion Date

September 21, 2023

Conditions

Healthy Volunteers

Interventions

DRUG

TAK-951

TAK-951 SC injection

DRUG

Placebo

TAK-951 matching placebo SC injection

Trial Locations (2)

66219

ICON, Lenexa

84124

ICON, Salt Lake City

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY

NCT06610279 - A Study of TAK-951 in Healthy Adults | Biotech Hunter | Biotech Hunter